Lineage Cell Therapeutics, Inc. (LCTX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 307.52
P/B Ratio
↑
7.27
↑+78% vs avg
5yr avg: 4.08
30Y Low1.2·High76.4
ROE
↓
-105.6%
↑-117% vs avg
5yr avg: -48.6%
30Y Low-154%·High32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LCTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lineage Cell Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $333M | $384M | $101M | $188M | $199M | $403M | $264M | $130M | $115M | $246M | $359M |
| Enterprise Value | $295M | $346M | $57M | $156M | $191M | $350M | $235M | $125M | $94M | $211M | $341M |
| P/E Ratio → | -4.89 | — | — | — | — | — | — | — | — | — | 10.62 |
| P/S Ratio | 22.88 | 26.40 | 10.59 | 21.04 | 13.51 | 103.45 | 341.63 | 87.63 | 81.55 | 137.35 | 159.59 |
| P/B Ratio | 7.27 | 8.87 | 1.31 | 3.03 | 2.76 | 4.43 | 2.78 | 1.16 | 1.25 | 1.50 | 2.75 |
| P/FCF | — | — | — | — | 307.52 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 187.59 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LCTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 23.76 | 6.03 | 17.41 | 13.00 | 89.86 | 304.42 | 84.71 | 66.50 | 117.64 | 151.55 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 295.97 | — | — | — | — | — | — |
LCTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lineage Cell Therapeutics, Inc. earns an operating margin of -251.6%. Operating margins have expanded from -276.5% to -251.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -105.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 96.5% | 92.5% | 95.0% | 63.4% | 50.2% | 72.1% | 78.7% | 90.6% | 84.1% |
| Operating Margin | -251.6% | -251.6% | -226.1% | -276.5% | -153.2% | -1263.1% | -3421.3% | -2630.3% | -2951.6% | -2170.9% | -2618.4% |
| Net Profit Margin | -436.5% | -436.5% | -195.9% | -240.2% | -178.7% | -1104.2% | -2671.3% | -792.2% | -3247.9% | -1114.7% | 1490.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -105.6% | -105.6% | -26.8% | -32.1% | -32.3% | -46.3% | -20.0% | -11.5% | -35.9% | -13.6% | 32.4% |
| ROA | -56.3% | -56.3% | -17.4% | -19.1% | -17.6% | -30.5% | -17.7% | -10.3% | -33.5% | -12.7% | 28.3% |
| ROIC | -141.9% | -141.9% | -50.9% | -39.5% | -33.0% | -70.8% | -22.9% | -32.8% | -31.4% | -24.2% | -58.3% |
| ROCE | -36.5% | -36.5% | -23.6% | -26.3% | -19.4% | -43.2% | -24.1% | -36.4% | -32.0% | -25.9% | -54.6% |
LCTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $41M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.03 | 0.05 | 0.05 | 0.03 | 0.04 | 0.05 | 0.02 | 0.01 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.89 | -0.56 | -0.52 | -0.10 | -0.58 | -0.30 | -0.04 | -0.23 | -0.21 | -0.14 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -11.55 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -3.84 | -56.22 | -78.94 |
Net cash position: cash ($41M) exceeds total debt ($2M)
LCTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lineage Cell Therapeutics, Inc.'s current ratio of 5.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.14x to 5.20x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.20 | 5.20 | 3.65 | 2.14 | 3.16 | 2.37 | 5.66 | 8.86 | 5.34 | 6.20 | 2.90 |
| Quick Ratio | 5.20 | 5.20 | 3.65 | 2.14 | 3.16 | 2.37 | 5.66 | 8.86 | 5.34 | 6.20 | 2.90 |
| Cash Ratio | 4.91 | 4.91 | 3.42 | 1.98 | 3.05 | 1.24 | 5.35 | 4.73 | 4.51 | 5.55 | 2.57 |
| Asset Turnover | — | 0.13 | 0.08 | 0.09 | 0.12 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 22.34 | 24.52 | 30.40 | 7.37 | 4762.99 | 1.89 | 6109.68 | 958.64 | 620.42 | 187.52 |
LCTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lineage Cell Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.1% | 29.8% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | 9.4% |
| FCF Yield | — | — | — | — | 0.3% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.4% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 30.0% | 0.4% | 0.0% |
| Shares Outstanding | — | $230M | $200M | $173M | $170M | $165M | $150M | $146M | $127M | $114M | $100M |
Peer Comparison
Compare LCTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LCTXYou | $333M | -4.9 | — | — | — | -251.6% | -105.6% | -141.9% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 CELC | $6B | -46.2 | — | — | — | — | -87.5% | -50.3% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 RGNX | $527M | -2.3 | — | — | 59.7% | -280.0% | -79.5% | -53.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See LCTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LCTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LCTX vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonLCTX — Frequently Asked Questions
Quick answers to the most common questions about buying LCTX stock.
What is Lineage Cell Therapeutics, Inc.'s P/E ratio?
Lineage Cell Therapeutics, Inc.'s current P/E ratio is -4.9x. The historical average is 10.6x.
What is Lineage Cell Therapeutics, Inc.'s ROE?
Lineage Cell Therapeutics, Inc.'s return on equity (ROE) is -105.6%. The historical average is -61.0%.
Is LCTX stock overvalued?
Based on historical data, Lineage Cell Therapeutics, Inc. is trading at a P/E of -4.9x. Compare with industry peers and growth rates for a complete picture.
What are Lineage Cell Therapeutics, Inc.'s profit margins?
Lineage Cell Therapeutics, Inc. has -251.6% operating margin.